Samsung Biologics Participates in 'CPHI 2023'... Pursuing Global Customer Orders

Participation as Official Partner of CPHI
Operation of Large-scale Eco-friendly Exclusive Booth
Introduction of 5th Plant and Customized Development Solutions

Samsung Biologics announced on the 23rd that it will participate in the 'Convention on Pharmaceutical Ingredients Worldwide 2023' (CPHI 2023), the largest pharmaceutical and bio conference in Europe.

Samsung Biologics' CPHI 2023 booth. [Photo by Samsung Biologics]

CPHI is a representative event of the global pharmaceutical and bio industry, held annually in major European countries on a rotating basis. This year, it will take place in Barcelona, Spain, from the 24th to the 26th of this month (local time) for a total of three days. More than 2,500 companies from 170 countries will participate, and over 45,000 visitors are expected to attend the exhibition during the event.

Samsung Biologics has participated in CPHI every year since 2018 with a dedicated booth. This year as well, it plans to set up a large-scale booth of 225㎡ (approximately 68 pyeong) in a prime location within the exhibition hall and pursue global customer orders through business networking.

In particular, considering the European environment where interest in responding to climate change is rising, the booth will be constructed using eco-friendly materials such as recycled materials, and printed brochures will be replaced by digital QR codes.

The booth walls will feature wall graphics highlighting key competitive advantages such as the world's largest production capacity (604,000ℓ) and new technology platforms. First, it will introduce Plant 5, with a capacity of 180,000ℓ, which marked the beginning of the 2nd Bio Campus era after construction started in April. When Plant 5 is completed as scheduled in April 2025, Samsung Biologics' total production capacity will increase to 784,000ℓ, further widening the gap with competitors as the world's number one.

Additionally, it will introduce the 'Customized CMC Solution,' a service package launched in August to improve contract development (CDO) efficiency. Through this solution, customers can receive tailored services optimized for the characteristics and development strategies of each candidate substance. Samsung Biologics plans to actively pursue CDO customer orders through this.

The booth will also have a separate lounge space for customer meetings and on-site customer support to facilitate partnership discussions.

Meanwhile, Samsung Biologics will strengthen its brand image by participating as an official partner of the CPHI event this year. Before the opening, the company logo will be advertised on the CPHI website and participant registration pages, and during the event, banner advertisements will be displayed along major routes including the main lobby of the exhibition hall, floor guide boards, and even on the CPHI mobile application.

Samsung Biologics' booth at CPHI 2023.
[Photo by Samsung Biologics]

This content was produced with the assistance of AI translation services.